Lantern Pharma Reports Positive Phase 1a Data For LP-184 In Advanced Solid Tumors
I'm PortAI, I can summarize articles.
Lantern Pharma Inc. reported positive results from its Phase 1a study of LP-184 in advanced solid tumors, showing durable disease control in patients with DDR pathway deficiencies. The study met safety and tolerability endpoints, and Lantern plans to advance LP-184 into Phase 1b/2 trials.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments